-
1
-
-
34848870352
-
Bortezomib for the treatment of mantle cell lymphoma
-
Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291-4.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5291-5294
-
-
Kane, R.C.1
Dagher, R.2
Farrell, A.3
Ko, C.W.4
Sridhara, R.5
Justice, R.6
-
2
-
-
84860436602
-
Advances in the understanding of mechanisms and therapeutic use of bortezomib
-
Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;12:471-80.
-
(2011)
Discov Med
, vol.12
, pp. 471-480
-
-
Mujtaba, T.1
Dou, Q.P.2
-
3
-
-
27944431658
-
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
-
Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005;31:591-602.
-
(2005)
Cancer Treat Rev
, vol.31
, pp. 591-602
-
-
Jackson, G.1
Einsele, H.2
Moreau, P.3
Miguel, J.S.4
-
4
-
-
33644845743
-
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
-
Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-6.
-
(2006)
Structure
, vol.14
, pp. 451-456
-
-
Groll, M.1
Berkers, C.R.2
Ploegh, H.L.3
Ovaa, H.4
-
5
-
-
0033817518
-
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341
-
Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3719-3728
-
-
Frankel, A.1
Man, S.2
Elliott, P.3
Adams, J.4
Kerbel, R.S.5
-
6
-
-
0036181371
-
Development of the proteasome inhibitor PS-341
-
Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
-
(2002)
Oncologist
, vol.7
, pp. 9-16
-
-
Adams, J.1
-
7
-
-
0034981649
-
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
-
Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-22.
-
(2001)
J Cell Biochem
, vol.82
, pp. 110-122
-
-
Shah, S.A.1
Potter, M.W.2
McDade, T.P.3
Ricciardi, R.4
Perugini, R.A.5
Elliott, P.J.6
-
8
-
-
0034902354
-
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
-
Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1419-1428
-
-
Sunwoo, J.B.1
Chen, Z.2
Dong, G.3
Yeh, N.4
Crowl Bancroft, C.5
Sausville, E.6
-
9
-
-
21344469223
-
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiplemyeloma
-
Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiplemyeloma. Br J Haematol 2005;129:776-83.
-
(2005)
Br J Haematol
, vol.129
, pp. 776-783
-
-
Jagannath, S.1
Durie, B.G.2
Wolf, J.3
Camacho, E.4
Irwin, D.5
Lutzky, J.6
-
10
-
-
18144431710
-
Mitochondrialmediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines
-
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrialmediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-36.
-
(2005)
Cancer Res
, vol.65
, pp. 3828-3836
-
-
Landowski, T.H.1
Megli, C.J.2
Nullmeyer, K.D.3
Lynch, R.M.4
Dorr, R.T.5
-
11
-
-
53349101501
-
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells
-
Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008;7:2298-307.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2298-2307
-
-
Gu, H.1
Chen, X.2
Gao, G.3
Dong, H.4
-
12
-
-
0242496212
-
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
-
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 14374-14379
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
Chauhan, D.4
Fanourakis, G.5
Gu, X.6
-
13
-
-
2342667387
-
The development of proteasome inhibitors as anticancer drugs
-
Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
-
(2004)
Cancer Cell
, vol.5
, pp. 417-421
-
-
Adams, J.1
-
14
-
-
0027980321
-
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
-
Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
-
(1994)
Cell
, vol.78
, pp. 773-785
-
-
Palombella, V.J.1
Rando, O.J.2
Goldberg, A.L.3
Maniatis, T.4
-
15
-
-
0346505340
-
The IKK NF-kappa B system: A treasure trove for drug development
-
Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
-
(2004)
Nat Rev Drug Discov
, vol.3
, pp. 17-26
-
-
Karin, M.1
Yamamoto, Y.2
Wang, Q.M.3
-
16
-
-
0037342894
-
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
-
Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1136-1144
-
-
Ma, M.H.1
Yang, H.H.2
Parker, K.3
Manyak, S.4
Friedman, J.M.5
Altamirano, C.6
-
17
-
-
0033121314
-
Role of NFkappaB in the rescue of multiple myeloma cells from glucocorticoidinduced apoptosis by bcl-2
-
Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NFkappaB in the rescue of multiple myeloma cells from glucocorticoidinduced apoptosis by bcl-2. Blood 1999;93:3044-52.
-
(1999)
Blood
, vol.93
, pp. 3044-3052
-
-
Feinman, R.1
Koury, J.2
Thames, M.3
Barlogie, B.4
Epstein, J.5
Siegel, D.S.6
-
18
-
-
84857668451
-
Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells
-
Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS One 2012;7:e32584.
-
(2012)
PLoS One
, vol.7
, pp. e32584
-
-
Jia, L.1
Gopinathan, G.2
Sukumar, J.T.3
Gribben, J.G.4
-
19
-
-
22244454745
-
Differential regulation of noxa in normalmelanocytes andmelanoma cells by proteasome inhibition: Therapeutic implications
-
Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, et al. Differential regulation of noxa in normalmelanocytes andmelanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
-
(2005)
Cancer Res
, vol.65
, pp. 6294-6304
-
-
Fernandez, Y.1
Verhaegen, M.2
Miller, T.P.3
Rush, J.L.4
Steiner, P.5
Opipari, A.W.6
-
20
-
-
37649000950
-
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
-
Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 2007;104:19488-93.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 19488-19493
-
-
Nikiforov, M.A.1
Riblett, M.2
Tang, W.H.3
Gratchouck, V.4
Zhuang, D.5
Fernandez, Y.6
-
21
-
-
84857368471
-
Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
-
Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, et al. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med 2012;90:45-54.
-
(2012)
J Mol Med
, vol.90
, pp. 45-54
-
-
Befani, C.D.1
Vlachostergios, P.J.2
Hatzidaki, E.3
Patrikidou, A.4
Bonanou, S.5
Simos, G.6
-
22
-
-
77951598447
-
The chemotherapeutic agent bortezomib induces the formation of stress granules
-
Fournier MJ, Gareau C, Mazroui R. The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int 2010;10:12.
-
(2010)
Cancer Cell Int
, vol.10
, pp. 12
-
-
Fournier, M.J.1
Gareau, C.2
Mazroui, R.3
-
23
-
-
17844399285
-
The enigmatic role of cyclin D1 in multiple myeloma
-
Lesage D, Troussard X, Sola B. The enigmatic role of cyclin D1 in multiple myeloma. Int J Cancer 2005;115:171-6.
-
(2005)
Int J Cancer
, vol.115
, pp. 171-176
-
-
Lesage, D.1
Troussard, X.2
Sola, B.3
-
24
-
-
33644875054
-
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
-
O'Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005;6:191-9.
-
(2005)
Clin Lymphoma Myeloma
, vol.6
, pp. 191-199
-
-
O'Connor, O.A.1
-
25
-
-
33748682930
-
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model
-
Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-47.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 1238-1247
-
-
Ishii, Y.1
Pirkmaier, A.2
Alvarez, J.V.3
Frank, D.A.4
Keselman, I.5
Logothetis, D.6
-
26
-
-
0028871496
-
Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique
-
Kocher O, Cheresh P, Brown LF, Lee SW. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res 1995;1:1209-15.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1209-1215
-
-
Kocher, O.1
Cheresh, P.2
Brown, L.F.3
Lee, S.W.4
-
27
-
-
0030017442
-
Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth
-
Kocher O, Cheresh P, Lee SW. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol 1996;149:493-500.
-
(1996)
Am J Pathol
, vol.149
, pp. 493-500
-
-
Kocher, O.1
Cheresh, P.2
Lee, S.W.3
-
28
-
-
36949008406
-
MAP17 inhibits Mycinduced apoptosis through PI3K/AKT pathway activation
-
Guijarro MV, Link W, Rosado A, Leal JF, Carnero A. MAP17 inhibits Mycinduced apoptosis through PI3K/AKT pathway activation. Carcinogenesis 2007;28:2443-50.
-
(2007)
Carcinogenesis
, vol.28
, pp. 2443-2450
-
-
Guijarro, M.V.1
Link, W.2
Rosado, A.3
Leal, J.F.4
Carnero, A.5
-
30
-
-
33846210072
-
Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi
-
Lanaspa MA, Giral H, Breusegem SY, Halaihel N, Baile G, Catalan J, et al. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am J Physiol Renal Physiol 2007;292:F230-42.
-
(2007)
Am J Physiol Renal Physiol
, vol.292
, pp. F230-F242
-
-
Lanaspa, M.A.1
Giral, H.2
Breusegem, S.Y.3
Halaihel, N.4
Baile, G.5
Catalan, J.6
-
31
-
-
0141813477
-
Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells
-
Pribanic S, Gisler SM, Bacic D, Madjdpour C, Hernando N, Sorribas V, et al. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells. Am J Physiol Renal Physiol 2003;285:F784-91.
-
(2003)
Am J Physiol Renal Physiol
, vol.285
, pp. F784-F791
-
-
Pribanic, S.1
Gisler, S.M.2
Bacic, D.3
Madjdpour, C.4
Hernando, N.5
Sorribas, V.6
-
32
-
-
84859497390
-
MAP17 and the double-edged sword of ROS
-
Carnero A. MAP17 and the double-edged sword of ROS. Biochim Biophys Acta 2012;1826:44-52.
-
(2012)
Biochim Biophys Acta
, vol.1826
, pp. 44-52
-
-
Carnero, A.1
-
33
-
-
0141813472
-
Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes
-
Blasco T, Aramayona JJ, Alcalde AI, Catalan J, Sarasa M, Sorribas V. Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes. Am J Physiol Renal Physiol 2003;285:F799-810.
-
(2003)
Am J Physiol Renal Physiol
, vol.285
, pp. F799-F810
-
-
Blasco, T.1
Aramayona, J.J.2
Alcalde, A.I.3
Catalan, J.4
Sarasa, M.5
Sorribas, V.6
-
34
-
-
84873903994
-
MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival
-
Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, et al. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One 2013;8:e56169.
-
(2013)
PLoS One
, vol.8
, pp. e56169
-
-
Perez, M.1
Praena-Fernandez, J.M.2
Felipe-Abrio, B.3
Lopez-Garcia, M.A.4
Lucena-Cacace, A.5
Garcia, A.6
-
35
-
-
35148842462
-
MAP17 enhances themalignant behavior of tumor cells through ROS increase
-
Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, et al. MAP17 enhances themalignant behavior of tumor cells through ROS increase. Carcinogenesis 2007;28:2096-104.
-
(2007)
Carcinogenesis
, vol.28
, pp. 2096-2104
-
-
Guijarro, M.V.1
Leal, J.F.2
Blanco-Aparicio, C.3
Alonso, S.4
Fominaya, J.5
Lleonart, M.6
-
36
-
-
84867401815
-
P38Alpha limits the contribution of MAP17 to cancer progression in breast tumors
-
Guijarro MV, Vergel M, Marin JJ, Munoz-Galvan S, Ferrer I, Ramon Y Cajal S, et al. p38alpha limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene 2012;31:4447-59.
-
(2012)
Oncogene
, vol.31
, pp. 4447-4459
-
-
Guijarro, M.V.1
Vergel, M.2
Marin, J.J.3
Munoz-Galvan, S.4
Ferrer, I.5
Cajal, R.Y.S.6
-
37
-
-
34548068225
-
MAP17 overexpression is a common characteristic of carcinomas
-
Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, et al. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis 2007c; 28:1646-52.
-
(2007)
Carcinogenesis
, vol.28
, pp. 1646-1652
-
-
Guijarro, M.V.1
Leal, J.F.2
Fominaya, J.3
Blanco-Aparicio, C.4
Alonso, S.5
Lleonart, M.6
-
38
-
-
33846438202
-
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
-
Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339-48.
-
(2007)
J Cell Biochem
, vol.100
, pp. 339-348
-
-
Moneo, V.1
Serelde, B.G.2
Fominaya, J.3
Leal, J.F.4
Blanco-Aparicio, C.5
Romero, L.6
-
39
-
-
67849130563
-
ToppGene suite for gene list enrichment analysis and candidate gene prioritization
-
Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009;37:W305-11.
-
(2009)
Nucleic Acids Res
, vol.37
, pp. W305-W311
-
-
Chen, J.1
Bardes, E.E.2
Aronow, B.J.3
Jegga, A.G.4
-
40
-
-
34147129816
-
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
-
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
-
(2007)
Blood
, vol.109
, pp. 3177-3188
-
-
Mulligan, G.1
Mitsiades, C.2
Bryant, B.3
Zhan, F.4
Chng, W.J.5
Roels, S.6
-
41
-
-
84894486878
-
IKKbeta inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
-
Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, et al. IKKbeta inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol 2014;44:1171-6.
-
(2014)
Int J Oncol
, vol.44
, pp. 1171-1176
-
-
Hideshima, H.1
Yoshida, Y.2
Ikeda, H.3
Hide, M.4
Iwasaki, A.5
Anderson, K.C.6
-
42
-
-
70349243697
-
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
-
Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-52.
-
(2009)
Blood
, vol.114
, pp. 1046-1052
-
-
Hideshima, T.1
Ikeda, H.2
Chauhan, D.3
Okawa, Y.4
Raje, N.5
Podar, K.6
-
43
-
-
66249085237
-
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib
-
Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res 2009;69:4415-23.
-
(2009)
Cancer Res
, vol.69
, pp. 4415-4423
-
-
Milani, M.1
Rzymski, T.2
Mellor, H.R.3
Pike, L.4
Bottini, A.5
Generali, D.6
-
44
-
-
78650041246
-
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
-
David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, et al. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 2010;116:5285-8.
-
(2010)
Blood
, vol.116
, pp. 5285-5288
-
-
David, E.1
Kaufman, J.L.2
Flowers, C.R.3
Schafer-Hales, K.4
Torre, C.5
Chen, J.6
-
45
-
-
67651146528
-
Effect of autophagy on multiple myeloma cell viability
-
Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther 2009;8:1974-84.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1974-1984
-
-
Hoang, B.1
Benavides, A.2
Shi, Y.3
Frost, P.4
Lichtenstein, A.5
-
46
-
-
84893825919
-
The four faces of autophagy: Implications for cancer therapy
-
Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014;74:647-51.
-
(2014)
Cancer Res
, vol.74
, pp. 647-651
-
-
Gewirtz, D.A.1
-
47
-
-
84878658221
-
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo
-
Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 2013;71:1567-76.
-
(2013)
Cancer Chemother Pharmacol
, vol.71
, pp. 1567-1576
-
-
Escalante, A.M.1
McGrath, R.T.2
Karolak, M.R.3
Dorr, R.T.4
Lynch, R.M.5
Landowski, T.H.6
-
48
-
-
7644242953
-
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
-
Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
-
(2004)
Mol Cell Biol
, vol.24
, pp. 9695-9704
-
-
Fribley, A.1
Zeng, Q.2
Wang, C.Y.3
-
49
-
-
33744539521
-
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
-
Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
-
(2006)
Blood
, vol.107
, pp. 4907-4916
-
-
Obeng, E.A.1
Carlson, L.M.2
Gutman, D.M.3
Harrington, W.J.4
Lee, K.P.5
Boise, L.H.6
-
50
-
-
79960982758
-
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
-
Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 2011;17:5101-12.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5101-5112
-
-
Weniger, M.A.1
Rizzatti, E.G.2
Perez-Galan, P.3
Liu, D.4
Wang, Q.5
Munson, P.J.6
-
51
-
-
77955712506
-
Bortezomibresistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
-
Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomibresistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010;24:1506-12.
-
(2010)
Leukemia
, vol.24
, pp. 1506-1512
-
-
Ri, M.1
Iida, S.2
Nakashima, T.3
Miyazaki, H.4
Mori, F.5
Ito, A.6
|